TIME: A phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC).
Elisabeth A. Quoix
Consultant or Advisory Role - Transgene (U)
Honoraria - Bristol-Myers Squibb; Lilly; Roche/Genentech; Transgene
John J. Nemunaitis
Stock Ownership - Gradalis
Tomasz Burzykowski
Consultant or Advisory Role - Transgene
Berangere Bastien
Employment or Leadership Position - Transgene
Stock Ownership - Transgene
Gisele Lacoste
Employment or Leadership Position - Transgene
Stock Ownership - Transgene